Risk factor levels, risk factor combinations, and residual coronary risk: Population-based estimates for secondary prevention patients using statins

European Journal of Preventive Cardiology

Volumn 19, Issue 1, 2012, Pages 109-117

  Krobot, Karl J ^a,b   Wagner, Alexander ^a   Siebert, Uwe ^b  

^a MSD Sharp and Dohme GmbH   (Germany)

^b UNIVERSITY FOR HEALTH SCIENCES   (Austria)

Author keywords

Coronary heart disease; hydroxymethylglutaryl CoA reductase inhibitors; residual risk; secondary prevention

Indexed keywords

ATORVASTATIN; CHOLESTEROL; FLUINDOSTATIN; HIGH DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN; MEVINOLIN; PRAVASTATIN; SIMVASTATIN; STATINE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ARTICLE; CARDIAC PATIENT; CHOLESTEROL BLOOD LEVEL; DRUG DOSE INCREASE; FEMALE; GERMANY; HUMAN; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; PRIMARY HEALTH CARE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK ASSESSMENT; RISK FACTOR; ADULT; AGED; CORONARY RISK; CROSS-SECTIONAL STUDY; DRUG MEGADOSE; MONOTHERAPY; PATIENT SAFETY; POPULATION RESEARCH; PREVALENCE; RISK REDUCTION; SECONDARY PREVENTION;

AGED; AGED, 80 AND OVER; ALGORITHMS; AUSTRIA; BIOLOGICAL MARKERS; CORONARY DISEASE; CROSS-SECTIONAL STUDIES; FATTY ACIDS, MONOUNSATURATED; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INDOLES; LIPIDS; MALE; MIDDLE AGED; PREVALENCE; PRIMARY HEALTH CARE; RECURRENCE; RETROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; SECONDARY PREVENTION; SIMVASTATIN; TIME FACTORS; TREATMENT OUTCOME;

EID: 84856925543     PISSN: 20474873     EISSN: 20474881     Source Type: Journal    
DOI: 10.1177/1741826710392668     Document Type: Article

References (13)

1. De Backer G. Evidence-based goals versus achievement in clinical practice in secondary prevention of coronary heart disease: findings in EUROASPIRE II. Atheroscler Suppl 2002; 2 4 13–16 discussion 6–7.
2. Grundy SM, Cleeman JI, Merz CN, Brewer HB Jr, Clark LT, Hunninghake DB., et al Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Arterioscler Thromb Vasc Biol 2004; 24(8): e149–e161.
3. Baigent C, Keech A, Kearney PM, Blackwell L, Buck G, Pollicino C., et al Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 2005; 366(9493): 1267–1278.
4. Rose G. Environmental health: problems and prospects. J R Coll Physicians Lond 1991; 25(1): 48–52.
5. Atkins D. Creating and synthesizing evidence with decision makers in mind: integrating evidence from clinical trials and other study designs. Med Care 2007; 45(10 Suppl 2): S16–S22.
6. Glasziou PP, Irwig LM. An evidence based approach to individualising treatment. Br Med J 1995; 311(7016): 1356–1359.
7. D’Agostino RB, Russell MW, Huse DM, Ellison RC, Silbershatz H, Wilson PW., et al Primary and subsequent coronary risk appraisal: new results from the Framingham study. Am Heart J 2000; 139(2 Pt 1): 272–281.
8. Knopp RH. Drug treatment of lipid disorders. N Engl J Med 1999; 341(7): 498–511.
9. Glasziou PP, Irwig L, Heritier S, Simes RJ, Tonkin A. Monitoring cholesterol levels: measurement error or true change?. Ann Intern Med 2008; 148(9): 656–661.
10. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994; 344(8934): 1383–1389.
11. Kuch B, Heier M, von Scheidt W, Kling B, Hoermann A, Meisinger C. 20-year trends in clinical characteristics, therapy and short-term prognosis in acute myocardial infarction according to presenting electrocardiogram: the MONICA/KORA AMI Registry (1985⊟2004). J Intern Med 2008; 264(3): 254–264.
12. Krobot KJ, Yin DD, Alemao E, Steinhagen-Thiessen E. Real-world effectiveness of lipid-lowering therapy in male and female outpatients with coronary heart disease: relation to pre-treatment low-density lipoprotein-cholesterol, pre-treatment coronary heart disease risk, and other factors. Eur J Cardiovasc Prev Rehabil 2005; 12(1): 37–45.
13. Robins JM, Hernán MA, Siebert U. Estimations of the effects of multiple interventions. In Ezzati MLA, Rodgers A, Murray CJL. Comparative quantification of health risks: Global and regional burden of disease attributable to selected major risk factors. Geneva: World Health Organization, 2004, 2191–2230.